Sarepta Therapeutics (NASDAQ:SRPT) had its target price increased by Citigroup from $174.00 to $188.00 in a research note released on Tuesday morning, The Fly reports. They currently have a buy rating on the biotechnology company’s stock.

Several other equities research analysts have also issued reports on the company. BidaskClub lowered Sarepta Therapeutics from a buy rating to a hold rating in a research note on Wednesday, October 31st. Piper Jaffray Companies dropped their price target on Sarepta Therapeutics from $189.00 to $168.00 and set an overweight rating for the company in a research note on Friday, October 26th. Zacks Investment Research raised Sarepta Therapeutics from a hold rating to a buy rating and set a $147.00 price target for the company in a research note on Tuesday, October 16th. Sanford C. Bernstein began coverage on Sarepta Therapeutics in a research note on Friday, October 12th. They set an outperform rating and a $170.00 price target for the company. Finally, Credit Suisse Group lifted their price target on Sarepta Therapeutics from $178.00 to $189.00 in a research note on Thursday, October 4th. Three equities research analysts have rated the stock with a hold rating, twenty-four have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $169.19.

SRPT stock traded down $7.54 during mid-day trading on Tuesday, hitting $125.46. 3,117,107 shares of the stock were exchanged, compared to its average volume of 1,061,749. The company has a quick ratio of 7.84, a current ratio of 8.85 and a debt-to-equity ratio of 0.65. Sarepta Therapeutics has a 12 month low of $50.68 and a 12 month high of $176.50.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, October 24th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.29). Sarepta Therapeutics had a negative return on equity of 23.67% and a negative net margin of 89.46%. The firm had revenue of $78.49 million for the quarter, compared to the consensus estimate of $78.84 million. On average, sell-side analysts forecast that Sarepta Therapeutics will post -4.38 EPS for the current year.

In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $140.50, for a total transaction of $936,713.50. Following the transaction, the director now owns 126,534 shares in the company, valued at approximately $17,778,027. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Douglas S. Ingram purchased 16,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, August 15th. The shares were acquired at an average price of $125.26 per share, for a total transaction of $2,004,160.00. Following the acquisition, the chief executive officer now owns 399,250 shares in the company, valued at $50,010,055. The disclosure for this purchase can be found here. 7.90% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the stock. First Quadrant L P CA purchased a new position in Sarepta Therapeutics during the 3rd quarter valued at about $130,000. Rockefeller Capital Management L.P. bought a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $162,000. Ffcm LLC bought a new stake in Sarepta Therapeutics during the 3rd quarter valued at approximately $162,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $185,000. Finally, Keybank National Association OH bought a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $206,000. Institutional investors own 89.84% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Recommended Story: Growth Stocks

The Fly

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.